share_log

BioNTech to Report Third Quarter Financial Results and Operational Update on November 9, 2021

BioNTech to Report Third Quarter Financial Results and Operational Update on November 9, 2021

BioNTech将于2021年11月9日公布第三季度财务业绩和最新运营情况
GlobeNewswire ·  2021/10/27 19:00

Mainz, Germany, October 27, 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") will announce its financial results for the third quarter on Tuesday, November 9th, 2021. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. ET (2.00 p.m. CET) to report its financial results and provide a corporate update for the third quarter 2021.

德国美因茨,2021年10月27日 (环球通讯社)--BioNTech SE(纳斯达克市场代码:BNTX,“BioNTech”或“The Company”)将于11月9日(星期二)公布第三季度财务业绩,2021年。BioNTech邀请投资者和普通公众参加当天上午8点与投资分析师举行的电话会议和网络直播。美国东部时间(下午2点)CET(CET:行情)报告其财务业绩,并提供2021年第三季度的公司最新情况。

The slide presentation and audio of the webcast will be available via this link.

网络广播的幻灯片演示文稿和音频将通过此链接提供。

To participate in the conference call, please dial the following numbers ten minutes prior to the start and provide the Conference ID:

要参加电话会议,请在会议开始前10分钟拨打以下号码并提供会议ID:

United States international:
United States domestic (toll-free):
Germany:
Conference ID:
+1 646 741 3167
+1 877 870 9135
+49 (0) 692 2222 625
6835174
美国国际:
美国国内(免费):
德国:
会议ID:
+1 646 741 3167
+1 877 870 9135
+49 (0) 692 2222 625
6835174

Participants may also access the slides and the webcast of the conference call via the "Events & Presentations" page of the Investor Relations section of the Company's website at https://biontech.de/. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.

与会者还可以通过公司网站https://biontech.de/.投资者关系部的“活动和演示”页面访问电话会议的幻灯片和网络直播。电话会议结束后不久,将可收看网络直播的重播,并在电话会议结束后30天内在公司网站上存档。

About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

关于BioNTech生物制药新技术公司是下一代免疫治疗公司,致力于开创癌症和其他严重疾病的新疗法。该公司利用广泛的计算发现和治疗药物平台来快速开发新型生物制药。其广泛的肿瘤学候选产品组合包括个性化和现成的基于mRNA的疗法、创新的嵌合抗原受体T细胞、双特异性检查点免疫调节剂、靶向癌症抗体和小分子。基于其在mRNA疫苗开发和内部制造能力方面的深厚专业知识,BioNTech及其合作者在其多样化的肿瘤学流水线的同时,正在为一系列传染病开发多种候选mRNA疫苗。BioNTech已经与多家全球制药合作伙伴建立了广泛的关系,其中包括Genmab、赛诺菲、拜耳动物健康公司、罗氏集团成员基因泰克、Regeneron、Genevant、复星国际制药公司和辉瑞公司。

For more information, please visit www.BioNTech.de.

欲了解更多信息,请访问www.BioNTech.de。

BioNTech Contacts

BioNTech联系人

Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de

投资者关系西尔克·马斯(Sylke Maas),博士。+49 (0)6131 9084 1074邮箱:Investors@biontech.de

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de

媒体关系茉莉·阿拉托维奇(Jasmina Alatovic)+49 (0)6131 9084 1513邮箱:media@biontech.de


译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发